Real-world study tests epcoritamab for hard-to-treat lymphoma
Disease control
Ongoing
This study tracks 150 adults with relapsed or refractory diffuse large B-cell lymphoma who have already tried at least two other treatments. Researchers want to see how well epcoritamab works outside of a controlled clinical trial, focusing on tumor shrinkage and side effects. Th…
Sponsor: Andrés José Maria Ferreri • Aim: Disease control
Last updated Apr 29, 2026 15:04 UTC